Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines

DNAALVAC-HIV gp120 delta V1 疫苗的 I 期 HIV 疫苗试验

• 批准号: 10487136
• 负责人: Genoveffa Franchini
• 金额: $ 953.45万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10487136
• 关键词: ALVAC; Adjuvant; Antibodies; Antigens; Binding; CD4 Positive T Lymphocytes; Communicable Diseases; DNA; DNA Vaccines; Development; Engineering; Epidemic; Epigenetic Process; Exposure to; Goals; Government; Grant; HIV; HIV Envelope Protein gp120; HIV Infections; HIV vaccine; Human; Hydroxides; Immune response; Immune system; Immunity; Immunoglobulin Variable Region; Inflammatory; Intellectual Property; Invertebrates; Investigation; Lead; Legal patent; Licensing; Macaca; Malignant Neoplasms; Mediating; Memory; Modeling; Natural Immunity; Natural Killer Cells; Phase; Preparation; Private Sector; Production; Proteins; Recombinants; Risk; SIV; T cell response; Testing; Thailand; Training; Translating; Vaccination; Vaccines; Virus; aluminum sulfate; antibody-dependent cell cytotoxicity; base; design; efficacy trial; gp160; monocyte; nonhuman primate; novel; pathogen; programs; trait; vaccine efficacy; vaccine trial

The project will exploit the DNA/ALVAC-HIV vaccine platform's ability to induce lasting trained monocyte memory in combination with a clade AE (A244 strain) V1-deleted HIV-gp160 prime and a novel V1-deleted HIV gp120/alum protein boost. The deletion of V1 from the gp120 envelope will be specially engineered to minimize antibody interference and elicit a high level of antibodies to V2, the primary correlate of risk in RV144. Alum hydroxide will be used as adjuvant for its ability to maximize the induction of trained immunity (through its ability to induce IL-1B) and CD4+ T-cell responses that constituted the secondary correlate of decreased risk of HIV acquisition in RV144. The overall objective of this proposal is to design and produce both a novel HIV V1-deleted A244 gp160 (A244 DeltaV1 gp160) DNA vaccine and a novel HIV V1-deleted A244 gp120 (A244 DeltaV1 gp120) in GMP conditions for testing in a phase I human HIV vaccine trial. These immunogens will first be tested in macaques to assess whether this approach also induces long-lasting, non-interfering antibodies, innate monocyte memory, and adaptive CD4+ T-cells with a low inflammatory profile in humans. The investigation of protective monocyte, or NK memory trained immunity, will prove beneficial in combatting additional infectious diseases and cancer. Evolutionary conserved from invertebrates, trained immunity is an ancient trait of the human immune system that is defined by durable epigenetic reprogramming of monocytes, providing the first line of defense against pathogens .This will lead not only to the production and testing of a novel HIV vaccine, but also to the thorough investigation of unexplored host protective immune responses in non-human primates (NHP) whose immune system mirrors that of humans.

该项目将利用DNA/ALVAC-HIV疫苗平台诱导持久训练的单核细胞记忆的能力，结合进化枝AE（A244株）V1缺失的HIV-gp 160引物和新型V1缺失的HIV gp 120/明矾蛋白加强。从gp 120包膜中删除V1将被特别工程化，以最大限度地减少抗体干扰，并引发高水平的V2抗体，V2是RV 144风险的主要相关因素。氢氧化铝将用作佐剂，因为其能够最大限度地诱导训练免疫（通过其诱导IL-1B的能力）和CD 4 + T细胞应答，这构成了RV 144中HIV感染风险降低的次要相关性。本提案的总体目标是在GMP条件下设计和生产新型HIV V1-缺失A244 gp 160（A244 DeltaV 1 gp 160）DNA疫苗和新型HIV V1-缺失A244 gp 120（A244 DeltaV 1 gp 120），用于I期人HIV疫苗试验。这些免疫原将首先在猕猴中进行测试，以评估这种方法是否也在人类中诱导持久的非干扰性抗体、先天单核细胞记忆和具有低炎症特征的适应性CD 4 + T细胞。保护性单核细胞或NK记忆训练免疫的研究将证明有益于对抗其他传染病和癌症。从无脊椎动物进化而来，训练免疫是人类免疫系统的一个古老特征，由单核细胞的持久表观遗传重编程定义，提供对抗病原体的第一道防线。这不仅将导致新型艾滋病毒疫苗的生产和测试，而且对非人灵长类动物（NHP）中未探索的宿主保护性免疫反应进行了彻底调查其免疫系统与人类相似